Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open-label, Multi-centre Phase 3b Study to Assess the Efficacy and Safety of Personalized Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A

NCT02256917 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT02256917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02256917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open-label, Multi-centre Phase 3b Study to Assess the Efficacy and Safety of Personalized Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2015
Completion date
September 30, 2018
Enrollment
58 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

severe haemophilia a